A novel score predicts mortality after transjugular intrahepatic portosystemic shunt: MOTS - Modified TIPS Score

Liver Int. 2022 Aug;42(8):1849-1860. doi: 10.1111/liv.15236. Epub 2022 Apr 1.

Abstract

Background and aims: The high risk for severe shunting-related post-interventional complications demands a stringent selection of candidates for transjugular intrahepatic portosystemic shunt (TIPS). We aimed to develop a simple and reliable tool to accurately predict early post-TIPS mortality.

Methods: 144 cases of TIPS implantation were retrospectively analysed. Using univariate and multivariate Cox regression analysis of factors predicting mortality within 90 days after TIPS, a score integrating urea, international normalized ratio (INR) and bilirubin was developed. The Modified TIPS-Score (MOTS) ranges from 0 to 3 points: INR >1.6, urea >71 mg/dl and bilirubin >2.2 mg/dl account for one point each. Additionally, MOTS was tested in an external validation cohort (n = 187) and its performance was compared to existing models.

Results: Modified TIPS-Score achieved a significant prognostic discrimination reflected by 90-day mortality of 8% in patients with MOTS 0-1 and 60% in patients with MOTS 2-3 (p < .001). Predictive performance (area under the curve) of MOTS was accurate (c = 0.845 [0.73-0.96], p < .001), also in patients with renal insufficiency (c = 0.830 [0.64-1.00], p = .02) and in patients with refractory ascites (c = 0.949 [0.88-1.00], p < .001), which are subgroups with particular room for improvement of post-TIPS mortality prediction. The results were reproducible in the validation cohort.

Conclusions: Modified TIPS-Score is a novel, practicable tool to predict post-TIPS mortality, that can significantly simplify clinical decision making. Its practical applicability should be further investigated.

Trial registration: ClinicalTrials.gov NCT03459378.

Keywords: hepatic encephalopathy; mortality; prediction; renal insufficiency; risk; transjugular intrahepatic portosystemic shunt.

MeSH terms

  • Ascites / complications
  • Bilirubin
  • Hepatic Encephalopathy* / complications
  • Humans
  • Liver Cirrhosis / complications
  • Portasystemic Shunt, Transjugular Intrahepatic*
  • Retrospective Studies
  • Treatment Outcome
  • Urea

Substances

  • Urea
  • Bilirubin

Associated data

  • ClinicalTrials.gov/NCT03459378